预后检测与评分系统在《全球血管指南》PLAN概念中用于慢性肢体威胁性缺血治疗的准确性系统评价
该系统评价与Meta分析评估了《全球血管指南》PLAN概念下多种预后检测对1年主要事件(无截肢生存和主要不良肢体事件)的预测准确性。共纳入96项研究、77种预测技术,其中13种满足标准。作者推荐在循证血运重建中使用GermanVasc CLTI评分、WIfI评分和全球肢体解剖分期系统(GLASS)。
要点
- 患者风险维度:GermanVasc CLTI评分AUC 71.8%,被认为在临床实践中最适用。
- 肢体严重程度维度:调整版WIfI评分AUC 78.8%为最佳预测评分,但缺乏外部验证。
- 解剖复杂度维度:无检测1年事件AUC超过70%,仅GLASS与血运重建可行性相关。
核心结论
- 在依据PLAN概念对CLTI患者进行循证血运重建时,作者推荐使用GermanVasc CLTI评分、WIfI评分和全球肢体解剖分期系统(GLASS)。
研究设计与样本
- 系统评价与Meta分析,纳入96项研究,描述77种独特预测技术,其中13种满足纳入标准。
- 从生存估计曲线重建个体患者数据,计算敏感性、特异性和受试者工作特征曲线下面积(AUC)。
- 纳入标准为AUC≥70%或与血运重建可行性相关,并评估检测的实际应用以提出PLAN实施建议。
主要发现
- 13种检测分为患者风险5项研究、肢体严重程度3项研究、解剖复杂度9项研究。
- 患者风险:钙卫蛋白和C反应蛋白生化评估AUC 82.0%,肌肉减少症影像学测量AUC 72.7%,GermanVasc CLTI评分AUC 71.8%。
- 肢体严重程度:调整版WIfI评分AUC 78.8%为最佳预测评分,但因缺乏外部验证,原始WIfI评分被认为最适用。
- 解剖复杂度:无检测1年事件估计AUC超过70%,仅GLASS与血运重建可行性相关。
关键数值与推荐
- GermanVasc CLTI评分AUC 71.8%,被认定为临床实践中最适用。
- 调整版WIfI评分AUC 78.8%,但缺乏外部验证。
- 原始WIfI评分因调整版缺乏外部验证而被认为最适用。
- 无解剖复杂度检测1年事件AUC超过70%,仅GLASS与血运重建可行性相关。
临床怎么用
- 作者推荐在CLTI循证血运重建的PLAN概念中采用GermanVasc CLTI评分、WIfI评分和GLASS。
局限性
- 调整版WIfI评分缺乏外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The 2019 Global Vascular Guidelines recommend risk assessment for evidence based revascularization based on the acronym PLAN: Patient risk, Limb severity and ANatomical complexity of disease. This meta-analysis compares a multitude of prognostic tests within these categories. METHODS: A systematic review and meta-analysis of tests that estimated 1-year major event (amputation-free survival and major adverse limb events) probability. Individual patient data were reconstructed from survival estimate curves. With presence or absence of major events, sensitivity, specificity, and area under receiver operating characteristics curves (AUC) were computed. Tests with an AUC ≥70%, or that correlated with revascularization feasibility were included. Practical application of tests was assessed to make a recommendation on PLAN implementation. RESULTS: Ninety-six studies describing 77 unique predictive techniques were included, of which thirteen were sufficient. These 13 tests were divided in four Patient risk (5 studies), three Limb severity (3 studies), and six ANatomical complexity of disease (9 studies). Patient risk: Three tests were included: biochemical assessment of calprotectin and C-reactive protein, radiologic measurement of sarcopenia, and predictive score with the GermanVasc chronic limb-threatening ischemia (CLTI) score. These tests scored AUCs of 82.0%, 72.7%, and 71.8%, respectively, of which the GermanVasc CLTI score was deemed most applicable in clinical practice. Limb severity: The adjusted Wound Ischemia foot Infection score (WIfI) resulted as best predictive score (AUC, 78.8%), but due to the lack of external validation, the original WIfI score was deemed best applicable. ANatomical complexity of disease: No test surpassed 70% AUC for 1-year event estimation, and was correlated with feasibility of revascularization, the latter only being served by the Global Limb Anatomic Staging System. CONCLUSIONS: In evidence-based revascularization in patients with CLTI according to the PLAN concept, we recommend to use GermanVasc, WIfI, and the Global Limb Anatomic Staging System.
引用
- Welling RHA, van Breugel M, van de Mortel M, et al. A systematic review of the accuracy of prognostic tests and scoring systems for use in the Global Vascular Guidelines' PLAN concept for the treatment of chronic limb threatening ischemia. J Vasc Surg. 2024. PMID: 39725246. doi:10.1016/j.jvs.2024.12.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。